Your browser doesn't support javascript.
loading
Evidence-based (S3) guideline for the treatment of psoriasis vulgaris - Update: "Therapeutic options" and "Efalizumab".
Nast, Alexander; Augustin, Matthias; Boehncke, Wolf-Henning; Klaus, Joachim; Mrowietz, Ulrich; Ockenfels, Hans-Michael; Philipp, Sandra; Reich, Kristian; Rosenbach, Thomas; Schlaeger, Martin; Sebastian, Michael; Sterry, Wolfram; Streit, Volker; Weisenseel, Peter; Rzany, Berthold.
Afiliação
  • Nast A; Division of Evidence Based Medicine (dEBM), Klinik für Dermatologie, Charité Universitätsmedizin Berlin, Campus Charité Mitte, Berlin. alexander.nast@charite.de
J Dtsch Dermatol Ges ; 8(1): 65-6, 2010 Jan.
Article em En, De | MEDLINE | ID: mdl-20096063
ABSTRACT
In February 2009, the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) had recommended the suspension of efalizumab's (Raptiva) marketing authorization, because its benefits in the treatment of psoriasis were modest, while there was a risk of serious side effects in patients receiving the medicine, including the occurrence of progressive multifocal leukoencephalopathy (PML). The guideline group has changed the guideline accordingly.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Psoríase / Guias de Prática Clínica como Assunto / Medicina Baseada em Evidências / Dermatologia / Anticorpos Monoclonais Tipo de estudo: Guideline Limite: Humans Idioma: De / En Ano de publicação: 2010 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Psoríase / Guias de Prática Clínica como Assunto / Medicina Baseada em Evidências / Dermatologia / Anticorpos Monoclonais Tipo de estudo: Guideline Limite: Humans Idioma: De / En Ano de publicação: 2010 Tipo de documento: Article